Ph 3 Trial of Disitamab Vedotin in 1L HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma meets Primary Endpoints of PFS and OS
“The strongly positive results of DV in combination with toripalimab as a first-line treatment for advanced urothelial carcinoma are encouraging. DV combined with toripalimab significantly improved PFS and OS, irrespective of cisplatin eligibility or HER2 expression level, which proves the success of HER2-ADC plus immunotherapy and represents a major breakthrough in the treatment of urothelial carcinoma worldwide. It is expected that the excellent performance of disitamab vedotin in subsequent studies will provide better decision-making basis for clinicians, bring more benefits to patients, and reshape the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo, principal investigator of the study and professor at Peking University Cancer Hospital.
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo